Morgan Pee
Payments from drug & device makers
Across 224 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$915
- AbbVie$550
- SK Life Science, Inc.$422
- Acorda Therapeutics, Inc$302
- Neurocrine Biosciences, Inc.$271
- Pfizer$259
- plus $2K from 20 others
What the payments were for
- Food & beverage$4,598100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 26 | $915 |
| AbbVie | 37 | $550 |
| SK Life Science, Inc. | 22 | $422 |
| Acorda Therapeutics, Inc | 20 | $302 |
| Neurocrine Biosciences, Inc. | 15 | $271 |
| Pfizer | 15 | $259 |
| Lundbeck LLC | 9 | $202 |
| Sumitomo Pharma America, Inc. | 9 | $200 |
| Lilly USA, LLC | 11 | $181 |
| Argenx US, Inc. | 6 | $171 |
| Otsuka America Pharmaceutical, Inc. | 8 | $165 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $141 |
| Axsome Therapeutics, Inc. | 7 | $133 |
| Impel Pharmaceuticals Inc. | 7 | $127 |
| Catalyst Pharmaceuticals, Inc. | 5 | $115 |
| Teva Pharmaceuticals USA, Inc. | 5 | $99 |
| Eisai Inc. | 3 | $65 |
| Jazz Pharmaceuticals Inc. | 2 | $53 |
| UCB, Inc. | 2 | $48 |
| Scilex Pharmaceuticals Inc. | 2 | $39 |
| Amneal Pharmaceuticals LLC | 2 | $33 |
| Harmony Biosciences LLC | 1 | $33 |
| Acadia Pharmaceuticals Inc | 1 | $22 |
| Biogen | 1 | $21 |
| Corium, LLC | 1 | $17 |
| Averitas Pharma Inc. | 1 | $14 |
How this compares
$4,598 in reported general payments places this provider in the 85th percentile of 3,415 family providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 14 | $123,854 |
| InbrijaLevodopa | 26 | $98,314 |
| NeuproRotigotine | 103 | $91,833 |
| Nurtec OdtRimegepant Sulfate | 61 | $91,331 |
| Emgality PenGalcanezumab-Gnlm | 48 | $39,013 |
| QuliptaAtogepant | 27 | $32,353 |
| AptiomEslicarbazepine Acetate | 11 | $28,164 |
| Aimovig AutoinjectorErenumab-Aooe | 35 | $27,834 |
| UbrelvyUbrogepant | 22 | $27,553 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $17,916 |
| Divalproex Sodium ErDivalproex Sodium | 205 | $7,323 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 14 | $5,977 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 194 | $5,624 |
| Levetiracetam | 274 | $4,843 |
| Ropinirole Hcl | 319 | $4,695 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $271 | $123,85414 claims |
| Acorda Therapeutics, IncInbrija | $302 | $98,31426 claims |
| UCB, Inc.Neupro | $48 | $91,833103 claims |
| PfizerNurtec Odt | $259 | $91,33161 claims |
| AbbVieQulipta, Ubrelvy | $550 | $59,90649 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $33 | $95213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,415 family providers in Alabama.
Other family in Boaz
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.